Anti-inflammatory effects of 12-HHT via epithelial barrier enhancement in colon organoids of normoganglionosis in Hirschsprungs disease

This study demonstrates that 12-HHT enhances epithelial barrier integrity and exerts anti-inflammatory effects in colonic organoids derived from Hirschsprung disease patients by upregulating tight junction proteins and mitigating TNF-α-induced barrier dysfunction.

The Gist

The Big Picture: A Leaky Fence in a Troubled Gut

Imagine the lining of your intestine as a high-security brick wall. Its job is to keep good stuff (nutrients) inside and bad stuff (bacteria, toxins) out. In a healthy person, this wall is tight, strong, and well-maintained.

However, in children with Hirschsprung's Disease (HD), a condition where parts of the colon lack nerve cells, this wall often gets damaged. After surgery to fix the nerve issue, many of these kids still suffer from a scary complication called Enterocolitis. Think of this as a "gut infection" where the wall becomes leaky, letting bacteria sneak in and cause massive inflammation (swelling and pain).

Scientists wanted to find a way to repair this wall and stop the inflammation. They discovered a potential "repair crew" called 12-HHT.

---

The Characters in the Story

1. The Organoids (The Mini-Guts):
   Instead of testing on real babies, the researchers took tiny samples of gut tissue from two groups of kids:

   • Group A (HD-N): Kids with Hirschsprung's who had surgery. Their gut tissue is "normoganglionic" (it has the nerves it needs now), but it's still prone to problems.
   • Group B (ARM): Kids with a different condition (Anorectal Malformation) used as a "healthy control" group.
     They grew these tissues into miniature, 3D gut models (organoids) in a lab. Think of these as tiny, self-contained "gut cities" where they could test treatments safely.

2. The 12-HHT (The Master Key):
   This is a natural substance our bodies make. The researchers found it acts like a master key that unlocks a specific door (called the BLT-2 receptor) on the gut cells. When this door opens, it tells the cells to start building and repairing.

3. The Tight Junctions (The Mortar):
   The "bricks" of our gut wall are cells. The "mortar" holding them together is made of special proteins called Tight Junctions (TJPs). If the mortar is weak, the wall leaks.

---

What Happened in the Lab?

The scientists ran a series of experiments to see if 12-HHT could fix the "leaky gut cities."

1. The Baseline Check (The Inspection)
First, they looked at the "cities" before any treatment. They found that the HD-N gut cities were already in worse shape than the healthy ARM cities. The "mortar" (Tight Junction proteins) was weaker, and the "repair doors" (BLT-2 receptors) were harder to find.

2. The Treatment (The Repair Crew Arrives)
They added 12-HHT to the mini-guts.

• The Result: The 12-HHT acted like a construction foreman. It shouted, "Build more mortar!" and the cells responded by producing more Tight Junction proteins. The wall became stronger and tighter.
• The Comparison: While it helped both groups, it worked best on the healthy ARM group, but it still made a significant difference in the HD-N group.

3. The Stress Test (The Storm)
To see if the repair was strong enough, the scientists simulated a disaster. They added TNF-alpha (a chemical that causes inflammation, like a storm) to the HD-N guts.

• Without 12-HHT: The storm blew the mortar away. The "leak" got worse, and the gut started screaming (producing inflammatory signals like IL-1B and IL-6).
• With 12-HHT: The 12-HHT acted like a reinforced shield. Even when the storm hit, the wall held together. The "leak" (measured by a glowing dye called FITC-dextran) was blocked, and the inflammation was kept under control.

---

The Conclusion: A New Hope for Repair

The study concludes that 12-HHT is a powerful tool. It doesn't just patch the hole; it actively strengthens the "mortar" (Tight Junctions) of the gut wall.

In simple terms:
If Hirschsprung's disease leaves the gut wall weak and leaky, causing painful infections, 12-HHT acts like a super-glue and a shield. It helps the gut cells rebuild their barriers and stop the inflammation before it starts. This could lead to new medicines that prevent or treat the serious gut infections that often plague children after their Hirschsprung's surgery.

Technical Summary

1. Problem Statement

Hirschsprung-associated enterocolitis (HAEC) is a severe and frequent postoperative complication in patients with Hirschsprung's disease (HD). A primary pathogenic mechanism proposed for HAEC is the impairment of epithelial barrier integrity. While the disease is characterized by the absence of ganglion cells in the distal colon, the study focuses on the normoganglionic segments (HD-N) of the colon, which are still prone to inflammation and barrier dysfunction. The research aims to identify a therapeutic agent capable of restoring barrier function and reducing inflammation in these specific tissues. Specifically, the study investigates the potential of 12-hydroxyheptadecatrienoic acid (12-HHT), an endogenous agonist for the leukotriene B4 receptor 2 (BLT-2), to enhance epithelial barrier integrity and exert anti-inflammatory effects.

2. Methodology

The study utilized a patient-derived organoid model to simulate the colonic environment:

• Sample Sources:
  • HD-N Group: Normoganglionic specimens from the rectal/rectosigmoid region of HD patients ($n=8$) obtained during pull-through surgery.
  • Control Group: Transverse colon specimens from patients with anorectal malformations (ARM) ($n=10$) obtained during colostomy closure.
• Organoid Generation: Epithelial cells were isolated using ethylenediaminetetraacetic acid (EDTA) and embedded in Matrigel to generate 3D colonic organoids.
• Baseline Characterization: Expression levels of tight junction proteins (TJPs)—specifically TJP1, TJP2, F11R (JAM-A), JAM2, CLDN1, CLDN3, and CLDN4—and the receptor LTB4R2 (BLT-2) were quantified via qPCR and immunoblotting.
• Intervention Protocols:
  • Long-term Treatment: Organoids were treated with 12-HHT at concentrations of 0.4, 2, or 10 $\mu$M for 7 days, followed by qPCR analysis.
  • Acute Inflammation Model: Organoids were exposed to Tumor Necrosis Factor-alpha (TNF-$\alpha$, 100 ng/mL) for 24 hours to induce inflammation. This was performed in the presence of either phosphate-buffered saline (control) or 12-HHT.
• Outcome Measures:
  • Gene Expression: Cytokines (IL1B, IL6) and TJPs were measured via qPCR.
  • Barrier Function: Paracellular permeability was assessed using FITC-dextran influx assays.

3. Key Contributions

• Novel Therapeutic Target: The study identifies 12-HHT as a potent candidate for treating HAEC by targeting the BLT-2 receptor pathway to restore epithelial barrier function.
• Disease-Specific Modeling: It establishes a comparative model using patient-derived organoids from HD-N tissue versus healthy ARM controls, highlighting intrinsic molecular differences in barrier proteins even in the "normal" ganglionic segments of HD patients.
• Mechanistic Insight: The research elucidates the mechanism by which 12-HHT counteracts TNF-$\alpha$-induced barrier disruption, specifically through the upregulation of tight junction proteins and suppression of pro-inflammatory cytokines.

4. Results

• Baseline Differences: HD-N organoids showed significantly lower baseline expression of F11R, JAM2, CLDN1, CLDN3, CLDN4, and LTB4R2 compared to ARM controls, suggesting an inherent vulnerability in HD-N epithelium.
• 12-HHT Efficacy on TJPs: Treatment with 12-HHT (at 2 and 10 $\mu$M) significantly upregulated tight junction proteins in both groups. The effect was more pronounced in the ARM group, but still significant in HD-N.
• Anti-inflammatory Effects in HD-N:
  • In HD-N organoids, 10 $\mu$M 12-HHT effectively suppressed the TNF-$\alpha$-induced elevation of pro-inflammatory cytokines IL1B and IL6.
  • The 10 $\mu$M concentration was superior to the 2 $\mu$M concentration in mitigating the downregulation of tight junction proteins caused by TNF-$\alpha$.
• Barrier Restoration: 12-HHT treatment significantly attenuated TNF-$\alpha$-induced FITC-dextran influx in HD-N organoids, confirming the restoration of epithelial barrier integrity.

5. Significance

This study provides compelling preclinical evidence that 12-HHT can serve as a therapeutic agent for preventing or treating Hirschsprung-associated enterocolitis. By activating the BLT-2 receptor, 12-HHT not only reinforces the physical epithelial barrier (via tight junction upregulation) but also dampens the inflammatory cascade triggered by TNF-$\alpha$. The findings suggest that targeting the 12-HHT/BLT-2 axis could be a viable strategy to improve postoperative outcomes in HD patients by addressing the underlying barrier dysfunction in the normoganglionic colon.